Клиническая микробиология и антимикробная химиотерапия (Mar 2024)

Ceftaroline fosamil – fifth-generation cephalosporin with anti-MRSA activity in the treatment of severe infections in pediatric practice

  • Andreeva I.V.,
  • Stetsiouk O.U.,
  • Kozlov R.S.

DOI
https://doi.org/10.36488/cmac.2024.1.40-58
Journal volume & issue
Vol. 26, no. 1
pp. 40 – 58

Abstract

Read online

Сeftaroline fosamil is a fifth-generation cephalosporin and a unique β-lactam and the only currently registered in the Russian Federation cephalosporin with activity against MRSA. Сeftaroline is approved for use in pediatric practice for the treatment of children with community-acquired pneumonia and complicated skin and soft tissue infections, including cases of patients with concomitant bacteremia. The place of ceftaroline in the treatment of severe and life-threatening infections in children is primarily due to its high activity against the key causative agents of community-acquired pneumonia and skin and soft tissue infections (first of all, S. pneumoniae and S. aureus, including MRSA), bactericidal mechanism of action, creation of effective concentrations and penetration into the infection’s site, low potential for resistance development, proven significant development of clinical effect, high clinical efficacy in these infections and favorable tolerability and safety profile. The review presents the results of the program of clinical evaluation of ceftaroline in children, analyzes current data on etiology and antimicrobial resistance of the key pathogens of community-acquired pneumonia and skin and soft tissue infections in the Russian Federation, defines the place of ceftaroline in clinical recommendations in children, and characterizes the patient’s profile to whom the prescription of ceftaroline in hospital is indicated.

Keywords